Please refer to the attached intimation.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences has disclosed its Key Performance Indicators spanning FY2022 to FY2026 and H1 comparisons, verified by Chartered Accountants Basheety & Joshi. Revenue grew significantly from ₹8,696 million in FY2022 to ₹21,925 million in FY2026, representing a 152% cumulative increase. EBITDA margin expanded from 15.07% to 29.78% over the same period, while PAT margin improved dramatically from 0.72% to 15.91%. Profit after tax grew from ₹62.26 million (FY2022) to ₹3,489.10 million (FY2026). The company also expanded its scientific staff headcount from 1,779 to 2,961 employees. Net working capital days improved from 204 days to 86 days, indicating better operational efficiency.
This strong financial performance with improving margins and profitability is positive for shareholders. The disclosure appears related to a capital raise under SEBI ICDR regulations, suggesting the company may be accessing equity markets to fund growth plans.